A trial of dasatinib for advanced cancers with certain gene changes (CA180385)
Cancer type:
Status:
Phase:
This trial looked at dasatinib for cancer that had spread into the surrounding tissue or to another part of the body. This is called advanced cancer. It was for people who had specific changes to 
called DDR2 and BRAF.
The trial was open for people to join between 2013 and 2014. The team analysed the results in 2016. There is a link to more information in the ‘Summary of results’ section below.
More about this trial
Dasatinib is a type of targeted cancer treatment called a tyrosine kinase inhibitor (TKI). It stops the signals that cancer cells use to divide and grow.
When this trial was done, doctors were already using dasatinib to treat . They wanted to find out if it was useful for other types of cancer.
The people in this trial had cancer with certain changes () in the DDR2 or BRAF gene.
Everyone taking part took dasatinib tablets once a day.
The main aims of the trial were to find out:
- how well dasatinib worked for cancers with these gene changes
- more about the side effects
- if other factors mean dasatinib works better or less well
Summary of results
We aim to add a lay summary of results to all the trials on our database. Unfortunately we have not been able to include a summary for this one.
There is more information about the results in the link below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
EU Clinical Trials Register - https://www.clinicaltrialsregister.eu/
Accessed March 2024
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Fiona Blackhall
Supported by
Bristol-Myers Squibb
Experimental Cancer Medicine Centre (ECMC)
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
